Volastra is a patient-focused clinical-stage biopharmaceutical company dedicated to the discovery and development of cancer medicines that target the biology of chromosomal instability.MORE ABOUT US
Chromosomal instability, or CIN, is a hallmark of cancer which is found in 60-80% of all tumors. It is associated with aggressive disease and poor survival.OUR SCIENCE
Our two differentiated lead clinical programs each target KIF18A, a protein which plays an essential role in the successful division of cancer cells.OUR PIPELINE
Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors
Volastra Therapeutics, a clinical-stage cancer biotechnology company, has appointed David Nicholson, Ph.D., as an independent member of its Board of Directors.
Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors
Volastra Therapeutics, a discovery and clinical-stage cancer biotechnology company, today announced the dosing of the first patient in a Phase I/II clinical trial evaluating VLS-1488.
Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023
NEW YORK, April 16, 2023 – Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today […]